Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).

Author: Chi, Gerald MD; Yee, Megan K. MPH; Amin, Alpesh N. MD; Goldhaber, Samuel Z. MD; Hernandez, Adrian F. MD; Hull, Russell D. MD; Cohen, Alexander T. MD; Harrington, Robert A. MD; Gibson, C. Michael MS, MD

Page: 91-94

http://ift.tt/2C9vIDE